EGFR and non-small cell lung carcinoma: Based on the LUX-Lung clinical trials, afatinib is currently approved for the treatment of metastatic NSCLC harboring EGFR S768I, L861Q and/or G719X alterations by the U.S. Food and Drug Administration (FDA) in 2018.